source
- FDA clears Roche's Wilserdly pill for certain ER-positive, HER2-negative breast cancersThe U.S. Food and Drug Administration has approved Roche's new oral therapy Wilserdly for a specific group of breast cancer patients. The drug is indicated for adults with estrogen receptor‑positi…
- Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancerRoche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…